Another new update on HDSA's websites from Marsha Miller! As Marsha wrote
me:

We now have four Phase III clinical trials underway or planned - creatine,
CoQ10, Dimebon, and ACR16 -with more to come from CHDI in the next couple of
years. Things are changing.

Amen and Halleluiah!!!!!!

The FDA approves a Phase IIb clinical trial of ACR16 for HD patients
http://www.hdsa.org/research/news/816.html
Marsha L. Miller, Ph.D., July 10, 2008

Huntington Study Group Upcoming Studies:
http://www.huntington-study-group.org/
July 2008 - CREST-E, HART and PREQUEL will soon be enrolling. Please check
back for updates on these and other potential future trials.

Florida families: the HDSA Center of Excellence at USF will be a part of the
HART Study. Stay tuned for more details from HSG and USF.

HD Clinical Studies: Both the EMEA (European Medicines Agency) and the FDA
have granted ACR16 orphan drug status for the treatment of Huntington's
disease:

United States - HART (Huntington's disease ACR16 Randomized Trial) Phase
IIb clinical trial 2nd half of 2008

Europe - Phase III MermaiHD (Multinational European Multicentre ACR16 study
in Huntington's Disease) on-going